Simultaneous isolation of hormone receptor–positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanisms

Recurrent hormone receptor–positive (HR+) breast cancer kills more than 600,000 women annually. Although HR+ breast cancers typically respond well to therapies, approximately 30% of patients relapse. At this stage, the tumors are usually metastatic and incurable. Resistance to therapy, particularly...

Descripción completa

Detalles Bibliográficos
Autores principales: Hogstrom, Jenny M., Cruz, Kayla A., Selfors, Laura M., Ward, Madelyn N., Mehta, Tejas S., Kanarek, Naama, Philips, Jordana, Dialani, Vandana, Wulf, Gerburg, Collins, Laura C., Patel, Jaymin M., Muranen, Taru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2023
Materias:
Methods and Resources
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415704/
https://www.ncbi.nlm.nih.gov/pubmed/37423299
http://dx.doi.org/10.1016/j.jbc.2023.105021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415704/
https://www.ncbi.nlm.nih.gov/pubmed/37423299
http://dx.doi.org/10.1016/j.jbc.2023.105021

Ejemplares similares